top of page
検索

OBI Pharma signs ADC platform licensing agreement with Novartis worth more than $2 billion

執筆者の写真: nuaxia
nuaxia
1 日前
読了時間: 2分

OBI Pharma has entered a global antibody-drug conjugate platform licensing agreement with Novartis carrying more than $2 billion in potential value, including a $30 million upfront payment and additional contingent milestones and royalties.


OBI Pharma announced on 13 November 2026 that it had signed a collaboration and licensing agreement granting Novartis exclusive worldwide rights to selected applications of its antibody-drug conjugate platform technologies, supporting the development of next-generation ADC therapies and novel payload approaches.


Under the agreement, OBI will receive $30 million upfront and may earn development, regulatory and commercial milestone payments that bring the total potential agreement value above $2 billion, together with tiered royalties; the majority of the headline value is contingent on future achievements, and the transaction is a technology licensing partnership rather than an acquisition of OBI Pharma or an approved drug.

Field

Content

Article Type

Deals

Licensor

OBI Pharma

Licensee

Novartis

Deal Type

Technology platform collaboration and licensing agreement

Announcement Date

13 November 2026

Agreement Status

Signed

Licensed Technology

Antibody-drug conjugate platform technologies

Technology Abbreviation

ADC

Development Focus

Next-generation antibody-drug conjugates

Additional Technology Focus

Novel ADC payload development

Licence Scope

Selected applications of OBI Pharma's ADC platform technologies

Licence Exclusivity

Exclusive

Territorial Rights

Worldwide

Upfront Payment

$30 million

Total Potential Deal Value

More than $2 billion

Additional Consideration

Development, regulatory and commercial milestone payments

Royalty Structure

Tiered royalties

Royalty Rates

Not disclosed in supplied summary

Milestone Payment Status

Contingent on future achievements

Guaranteed Total Deal Value

Not more than the disclosed upfront payment based on supplied information

Therapeutic Modality

Antibody-drug conjugates

Therapeutic Area

Oncology drug development

Asset Acquisition

No

Company Acquisition

No

Approved Medicine Included

Not reported

What Happened

OBI Pharma licensed selected ADC platform technologies to Novartis under an exclusive worldwide collaboration.

Why It Matters

The partnership provides a major pharmaceutical company with access to emerging ADC technology while potentially generating substantial future revenue for the technology developer.

Strategic Significance

Supports Novartis' exploration of next-generation targeted oncology therapies and validates commercial interest in OBI's platform.

Financial Significance

The agreement includes $30 million upfront and more than $2 billion in potential total value.

Financial Clarification

Most of the headline agreement value depends on future development, regulatory and commercial milestones.

Transaction Clarification

This is a licensing and collaboration agreement, not an acquisition.

Key Takeaway

Novartis has secured exclusive worldwide rights to selected OBI Pharma ADC technologies under a deal potentially worth more than $2 billion.

What to Watch

Selection of development programmes, preclinical and clinical progress, milestone achievements and future ADC pipeline disclosures.

Primary Source

OBI Pharma

Primary Source URL

https://www.obipharma.com/news/signs-collaboration-and-license-agreement-with-novartis/

Submitted Source

The Globe and Mail

Submitted Source URL

https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/8842040/obi-pharma-signs-adc-platform-collaboration-and-license-agreement-with-novartis/

Relevant Date

13 November 2026


Discover how nuaxia can support your next medical education initiative:

 
 
 

コメント

5つ星のうち0と評価されています。
まだ評価がありません

評価を追加
bottom of page